Vanguard Global Advisers
OLMA icon

Vanguard Global Advisers’s Olema Pharmaceuticals OLMA Stock Holding History

Vanguard Global Advisers’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
19,066
-21,665
-53% -$290K ﹤0.01% 2434
2026
Q1 		$607K Buy
+40,731
New +$907K ﹤0.01% 1943

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Global Advisers's OLMA Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Olema Pharmaceuticals (OLMA) stake by 53% in Q2 2026, selling an estimated $290K and leaving 19,066 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #2434.

Vanguard Global Advisers first reported a position in OLMA in Q1 2026 and has held it in 2 quarters since. The position peaked at $607K in Q1 2026. 183 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Vanguard Global Advisers held 19,066 shares of Olema Pharmaceuticals worth $239K as of Q2 2026.
  • Vanguard Global Advisers sold 21,665 Olema Pharmaceuticals shares in Q2 2026, an estimated $290K.
  • Olema Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2434 holding.
  • Vanguard Global Advisers first reported a position in Olema Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Olema Pharmaceuticals position peaked at $607K in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.